• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Editorial on Special Issue "Immunotherapy, Tumor Microenvironment and Survival Signaling".关于“免疫疗法、肿瘤微环境与生存信号”特刊的社论
Cancers (Basel). 2021 Dec 24;14(1):91. doi: 10.3390/cancers14010091.
2
Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.免疫疗法在靶向多发性骨髓瘤骨髓微环境中的作用：一种不断发展的治疗策略。
Pharmacotherapy. 2017 Jan;37(1):129-143. doi: 10.1002/phar.1871. Epub 2017 Jan 6.
3
Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.多发性骨髓瘤的成功治疗是否更近了一步？CAR-T 细胞是一个值得乐观的好理由。
Stem Cell Res Ther. 2021 Mar 29;12(1):217. doi: 10.1186/s13287-021-02283-z.
4
Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy.CAR T 细胞疗法中与肿瘤微环境友好相处。
Front Immunol. 2021 Feb 10;11:618387. doi: 10.3389/fimmu.2020.618387. eCollection 2020.
5
Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.靶向骨髓微环境中的免疫龛：多发性骨髓瘤免疫治疗的兴起。
Curr Cancer Drug Targets. 2017;17(9):782-805. doi: 10.2174/1568009617666170214103834.
6
CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.嵌合抗原受体 T 细胞增强对 B 细胞成熟抗原的敏感性，用于靶向治疗 B 细胞非霍奇金淋巴瘤和多发性骨髓瘤。
Mol Ther. 2018 Aug 1;26(8):1906-1920. doi: 10.1016/j.ymthe.2018.06.012. Epub 2018 Jun 18.
7
[Chimeric antigen receptor T-cell therapy for multiple myeloma].嵌合抗原受体T细胞疗法治疗多发性骨髓瘤
Rinsho Ketsueki. 2018;59(10):2189-2194. doi: 10.11406/rinketsu.59.2189.
8
Hematopoietic versus Solid Cancers and T Cell Dysfunction: Looking for Similarities and Distinctions.造血系统癌症与实体癌症及T细胞功能障碍：探寻异同
Cancers (Basel). 2021 Jan 14;13(2):284. doi: 10.3390/cancers13020284.
9
Next Generation CAR T Cells for the Immunotherapy of High-Grade Glioma.用于高级别胶质瘤免疫治疗的下一代嵌合抗原受体T细胞
Front Oncol. 2019 Feb 26;9:69. doi: 10.3389/fonc.2019.00069. eCollection 2019.
10
Novel progresses of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma.嵌合抗原受体（CAR）T细胞疗法在多发性骨髓瘤中的新进展。
Stem Cell Investig. 2021 Jan 15;8:1. doi: 10.21037/sci-2020-029. eCollection 2021.

本文引用的文献

1
Damage-Associated Molecular Patterns Modulation by microRNA: Relevance on Immunogenic Cell Death and Cancer Treatment Outcome.微小RNA对损伤相关分子模式的调控：与免疫原性细胞死亡及癌症治疗结果的相关性
Cancers (Basel). 2021 May 24;13(11):2566. doi: 10.3390/cancers13112566.
2
Engineering Metabolism of Chimeric Antigen Receptor (CAR) Cells for Developing Efficient Immunotherapies.构建嵌合抗原受体（CAR）细胞的代谢以开发高效免疫疗法。
Cancers (Basel). 2021 Mar 5;13(5):1123. doi: 10.3390/cancers13051123.
3
Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models.三特异性 CD19-CD20-CD22 双靶点 CAR-T 细胞在临床前模型中消除抗原异质性 B 细胞肿瘤。
Sci Transl Med. 2021 Mar 24;13(586). doi: 10.1126/scitranslmed.abc6401.
4
Novel CD37, Humanized CD37 and Bi-Specific Humanized CD37-CD19 CAR-T Cells Specifically Target Lymphoma.新型CD37、人源化CD37和双特异性人源化CD37-CD19嵌合抗原受体T细胞特异性靶向淋巴瘤。
Cancers (Basel). 2021 Feb 26;13(5):981. doi: 10.3390/cancers13050981.
5
Novel progresses of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma.嵌合抗原受体（CAR）T细胞疗法在多发性骨髓瘤中的新进展。
Stem Cell Investig. 2021 Jan 15;8:1. doi: 10.21037/sci-2020-029. eCollection 2021.
6
Chimeric antigen receptor T-cell therapy for melanoma.嵌合抗原受体T细胞疗法治疗黑色素瘤。
Expert Rev Clin Immunol. 2021 Mar;17(3):209-223. doi: 10.1080/1744666X.2021.1880895. Epub 2021 Jan 31.
7
The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment.免疫抑制性肿瘤微环境中髓源性抑制细胞与调节性T细胞之间的功能串扰
Cancers (Basel). 2021 Jan 8;13(2):210. doi: 10.3390/cancers13020210.
8
Cancer immunotherapy: special issue of BMB Reports in 2021.癌症免疫疗法：《BMB 报告》2021 年特刊
BMB Rep. 2021 Jan;54(1):1. doi: 10.5483/BMBRep.2021.54.1.002.
9
Tuft and Cancer Stem Cell Marker DCLK1: A New Target to Enhance Anti-Tumor Immunity in the Tumor Microenvironment.簇绒细胞和癌症干细胞标志物DCLK1：增强肿瘤微环境中抗肿瘤免疫的新靶点。
Cancers (Basel). 2020 Dec 17;12(12):3801. doi: 10.3390/cancers12123801.
10
Cancer Immunotherapy and Application of Nanoparticles in Cancers Immunotherapy as the Delivery of Immunotherapeutic Agents and as the Immunomodulators.癌症免疫疗法以及纳米颗粒在癌症免疫疗法中的应用，作为免疫治疗药物的递送载体和免疫调节剂。
Cancers (Basel). 2020 Dec 15;12(12):3773. doi: 10.3390/cancers12123773.

关于“免疫疗法、肿瘤微环境与生存信号”特刊的社论

Editorial on Special Issue "Immunotherapy, Tumor Microenvironment and Survival Signaling".

作者信息

Golubovskaya Vita

机构信息

Promab Biotechnologies, 2600 Hilltop Drive, Richmond, CA 94806, USA.

出版信息

Cancers (Basel). 2021 Dec 24;14(1):91. doi: 10.3390/cancers14010091.

DOI:10.3390/cancers14010091
PMID:35008254
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8750357/
Abstract

Recently, novel types of immunotherapies such as CAR-T cell therapy demonstrated efficacy in leukemia, lymphoma, and multiple myeloma [...].

摘要

最近，嵌合抗原受体T细胞（CAR-T）疗法等新型免疫疗法在白血病、淋巴瘤和多发性骨髓瘤中显示出疗效[...]。